Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 5/20 | 0.51 |
| ▸ | PTGDR2 | Q9Y5Y4 | 14/20 | 0.43 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.43 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | PTGIR | P43119 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13428115 | 0.89 | GPBAR1 (0.45) | GPBAR1PTGDR2TBXA2RPTGDRCYP3A4 | |
| SCHEMBL1923681 | 0.89 | GPBAR1 (0.56) | GPBAR1PTGDR2TBXA2RPTGDRCYP3A4 | |
| SCHEMBL13428445 | 0.88 | PTGDR2 (0.51) | PTGDR2 | |
| SCHEMBL1922804 | 0.88 | PTGDR2 (0.46) | GPBAR1PTGDR2TBXA2RPTGDRCYP3A4 | |
| SCHEMBL16501929 | 0.87 | MEN1 (0.41) | GPBAR1 | |
| SCHEMBL3370538 | 0.86 | GPBAR1 (0.44) | GPBAR1PTGDR2TBXA2RPTGDRCYP3A4 | |
| SCHEMBL13426387 | 0.85 | PTGDR2 (0.55) | GPBAR1PTGDR2TBXA2RPTGDRCYP3A4 | |
| SCHEMBL16509337 | 0.83 | GPBAR1 (0.46) | GPBAR1PTGDR2TBXA2RPTGDRCYP3A4 | |
| SCHEMBL3369014 | 0.83 | GPBAR1 (0.47) | GPBAR1PTGDR2TBXA2RPTGDRCYP3A4 | |
| SCHEMBL3366130 | 0.83 | PTGDR2 (0.49) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | claimed |
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| WO-2010037059-A2 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312974-A1 | HETEROARYL ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | PTGDR, PTGDR2, PTGER2 | GPBAR1 32/4885PTGDR2 2/4885TBXA2R 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.